Minerva Neurosciences - NERV Stock Forecast, Price & News

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Minerva Neurosciences in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" NERV shares.
View NERV analyst ratings or view top-rated stocks.

1 brokerages have issued twelve-month target prices for Minerva Neurosciences' stock. Their NERV share price forecasts range from $40.00 to $40.00. On average, they anticipate the company's stock price to reach $40.00 in the next year. This suggests a possible upside of 1,178.0% from the stock's current price.
View analysts price targets for NERV or view top-rated stocks among Wall Street analysts.

Minerva Neurosciences' stock was trading at $6.4080 at the beginning of 2022. Since then, NERV stock has decreased by 51.2% and is now trading at $3.13.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, November 14th 2022.
View our NERV earnings forecast.

Minerva Neurosciences, Inc. (NASDAQ:NERV) posted its earnings results on Monday, November, 8th. The biopharmaceutical company reported ($1.76) earnings per share for the quarter, hitting analysts' consensus estimates of ($1.76). During the same period last year, the company earned ($1.52) EPS.

Shares of Minerva Neurosciences reverse split on the morning of Tuesday, June 21st 2022. The 1-8 reverse split was announced on Tuesday, June 21st 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, June 21st 2022. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other Minerva Neurosciences investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), PTC Therapeutics (PTCT), Immunomedics (IMMU), VBI Vaccines (VBIV), Dynavax Technologies (DVAX), Gilead Sciences (GILD), Moderna (MRNA), T2 Biosystems (TTOO) and Advanced Micro Devices (AMD).

Minerva Neurosciences trades on the NASDAQ under the ticker symbol "NERV."

Minerva Neurosciences' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Millennium Management LLC (1.49%), Group One Trading L.P. (0.00%), FMR LLC (0.94%), Sei Investments Co. (0.71%), Renaissance Technologies LLC (0.67%) and State Street Corp (0.26%). Insiders that own company stock include David Kupfer, Frederick W Ahlholm, Geoff Race, Heek G Jan Van, Joseph H Reilly and Remy Luthringer.
View institutional ownership trends.

Shares of NERV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of NERV stock can currently be purchased for approximately $3.13.

Minerva Neurosciences (NASDAQ:NERV) has a market capitalization of $16.71 million and generates $41.18 million in revenue each year. The biopharmaceutical company earns $-49,910,000.00 in net income (profit) each year or ($9.23) on an earnings per share basis.

Minerva Neurosciences' mailing address is 1601 TRAPELO ROAD SUITE 286, WALTHAM MA, 02451. The official website for the company is www.minervaneurosciences.com. The biopharmaceutical company can be reached via phone at (617) 600-7373 or via email at wboni@minervaneurosciences.com.